Kiniksa Pharmaceuticals/$KNSA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
- Ticker
- $KNSA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 366
- Headquarters
- London, United Kingdom
- Website
- www.kiniksa.com
KNSA Metrics
BasicAdvanced
$7.2B
69.68
$1.32
0.04
-
Price and volume
Market cap
$7.2B
Beta
0.04
52-week high
$98.48
52-week low
$36.56
Average daily volume
760K
Financial strength
Current ratio
3.91
Quick ratio
3.125
Long term debt to equity
0.006
Total debt to equity
0.011
Profitability
EBITDA (TTM)
132.362
Gross margin (TTM)
54.27%
Net profit margin (TTM)
11.58%
Operating margin (TTM)
13.79%
Effective tax rate (TTM)
25.03%
Revenue per employee (TTM)
$2,580,000
Management effectiveness
Return on assets (TTM)
9.62%
Return on equity (TTM)
17.59%
Valuation
Price to earnings (TTM)
69.682
Price to revenue (TTM)
7.515
Price to book
10.19
Price to tangible book (TTM)
10.41
Price to free cash flow (TTM)
36.051
Free cash flow yield (TTM)
2.77%
Free cash flow per share (TTM)
2.559
Growth
Revenue change (TTM)
58.19%
Earnings per share change (TTM)
183.55%
3-year revenue growth (CAGR)
56.09%
3-year earnings per share growth (CAGR)
133.25%
What the Analysts think about KNSA
Analyst ratings (Buy, Hold, Sell) for Kiniksa Pharmaceuticals stock.
Analyst projections of the future price of Kiniksa Pharmaceuticals stock.
Bulls say / Bears say
ARCALYST revenue rose 58% year on year to $286 million in Q3, and Kiniksa raised its 2026 sales forecast to $1.045–$1.050 billion. The strong commercial momentum is already translating into higher reported earnings. (GlobeNewswire)
There is room for further uptake: only about 23% of the 14,000 patients with multiple annual recurrences were on ARCALYST at Q3, while more than 5,450 prescribers have written prescriptions. Continued patient and physician adoption could support further growth. (GlobeNewswire)
KPL-387’s Phase 2 data showed rapid, sustained improvement at the monthly dose selected for Phase 3, and the pivotal trial is now enrolling. A successful result could provide a next-generation option for recurrent pericarditis. (Kiniksa Pharmaceuticals)
Kiniksa remains heavily reliant on ARCALYST: Q3 product revenue was $286 million, equal to total revenue, leaving little revenue diversification if the drug’s sales weaken. (GlobeNewswire)
KPL-387 remains unproven in its pivotal trial, with data expected only in the second half of 2027 and a potential launch in 2028 or 2029. That leaves a long wait before the pipeline can add a second commercial growth driver. (GlobeNewswire)
Operating expenses rose to $231.7 million in Q3 from $156.8 million a year earlier, including higher collaboration, research and selling costs. If spending continues to rise quickly, it could limit how much of future sales growth reaches shareholders as profit. (BioSpace)
Data summarised monthly by Lightyear AI. Last updated on 27 Oct 2026.
KNSA Financial Performance
Revenues and expenses
KNSA Earnings Performance
Company profitability
Upcoming events
No upcoming events
KNSA News
AllArticlesVideos
Funds containing KNSA
Fund name | Fund size | $KNSA weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.44% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.44% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.44% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.30% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.30% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.